Webcast: Positive scientific ESAC opinion on GARD®skin – paving the way for OECD validation and opens new commercial opportunities
CEO Axel Sjöblad and Chief Scientist Henrik Johansson comment on the recently published ESAC opinion.
Entries by
Applicability domain of the GARD™skin Medical Device test for in vitro skin sensitization testing of medical devices
Poster presented at SOT 2021 Joshua Schmidt, Ron Brown and Rose-Marie Jenvert SenzaGen Inc., Raleigh, NC, USA, Risk Science Consortium LLC, Arnold, MD, USA, SenzaGen AB, Lund, Sweden. Download a copy Conclusion The chemical space of compounds tested in GARD closely approximates the chemical space of compounds known to be released from medical device materials. […]
Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response
Poster presented at SOT 2021 Henrik Johansson, Robin Gradin, Andy Forreryd, Joshua Schmidt SenzaGen AB, Lund, Sweden. SenzaGen Inc., Raleigh, NC. Download a copy Conclusion As an adaptation from the GARDskin assay, GARDskin Dose-Response is suitable for quantitative skin sensitizing potency assessment of chemicals. The experimental readout, referred to as cDV0, corresponds to the […]
SOT 2021 Recap: Spotlight on Dose-Response and the MDCPSS Best Overall Abstract Award Winner 🏅
SenzaGen had a busy program at SOT 2021. To highlight our expanding capabilities in in vitro skin toxicology, we took part in several activities and presented our novel assays for quantitative skin sensitizing potency assessment and medical device testing. Exhibitor Hosted Session: Dose-response for predicting skin sensitization potency Listen to SenzaGen’s Chief Scientist Dr Henrik Johansson presenting […]
Applicability of GARD™skin for Accurate Assessment of Challenging Substances in the Context of Skin Sensitization Testing
Poster presented at ACT 2020 J. Schmidt, A. Forreryd, H. Johansson, J. Li, A. Johansson SenzaGen, Inc., Raleigh, NC, USA, SenzaGen AB, Lund, Sweden Link to the poster Conclusion GARDskin demonstrated an overall high applicability for the evaluated challenging substances with 80% predictive accuracy compared to existing human data. GARDskin demonstrated excellent applicability for […]
Dose-Response Analysis in GARD™ for Assessment of Skin Sensitizer Potency
Poster presented at ACT 2020 J. Schmidt, A. Forreryd, R. Gradin, H. Johansson. SenzaGen Inc., Raleigh, NC., SenzaGen AB, Lund, Sweden. Link to the poster Conclusion As an adaptation from the GARDskin assay, GARDskin Dose-Response is suitable for quantitative skin sensitizing potency assessment of chemicals. The experimental readout, referred to as cDV0, corresponds to […]
Exploration of the GARD applicability domain – Skin sensitization assessment of UVCBs
Poster presented at Eurotox 2018 in collaboration with Lubrizol Download a copy U. I.Torstensdotter Mattson1, C. Humfrey2, O. Larne1, H. Johansson1, L. Sweet3 1SenzaGen, Lund, Sweden, 2Lubrizol, Derbyshire, United Kingdom, 3Lubrizol, Ohio, United States of America Conclusion This case study demonstrates the broadening of the applicability domain of the GARD assay when assessing UVCBs. Abstract […]
